Novo Nordisk considering sale of Ferrosan vitamin, OTC subsidiary.
This article was originally published in The Tan Sheet
Executive Summary
NOVO NORDISK CONSIDERING SALE OF FERROSAN VITAMIN/OTC BUSINESS, the Danish insulin and diabetes care products manufacturer ac-knowledged in a Sept. 25 release. Novo Nordisk said "an outright sale [of Ferrosan], as well as management buy-in and buy-out options, have been or are under consideration." Under a management buy-in, the company explained, a group from outside the company would purchase Ferrosan and run it.